Overview of Platelet Transfusion

Seminars in Hematology

Volumn 47, Issue 3, 2010, Pages 235-242

  McCullough, Jeffrey ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RHESUS ANTIGEN; THROMBOCYTE CONCENTRATE;

ALLOIMMUNIZATION; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PRIMARY PREVENTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

HUMANS; PLATELET COUNT; PLATELET TRANSFUSION; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 77953880514     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.04.001     Document Type: Article

References (72)

1. Murphy S., Heaton W.A. Rebulla P. Platelet production in the old world and the new. Transfusion 1996, 36:751-754.
2. Whitaker B.I., Green J., King M.R. The 2007 nationwide Blood Collection and Utilization Survey Report 2008, Department of Health and Human Services, Washington, DC.
3. Moroff G., Friedman A., Robkin-Kline L., Gautier G., Luban N.L.C. Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion 1984, 24:144-146.
4. Filip D.J., Aster R.H. Relative hemostatic effectiveness of human platelets stored at 4°C and 22°C. J Lab Clin Med 1978, 91:618-624.
5. Slichter S.J., Harker L.A. Preparation and storage of platelet concentrates-II. Storage and variables influence platelet viability and function. Br J Haematol 1976, 34:403-419.
6. Daly P.A., Schiffer C.A., Aisner J., Wiernik P.H. Platelet transfusion therapy: one hour posttransfusion increments are valuable in predicting the need for HLA matched preparations. JAMA 1980, 243:435-438.
7. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962, 266:905-908.
8. Schiffer C.A., Anderson K.C., Bennett C.L., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1519-1538.
9. Slichter S.J. Controversies in platelet transfusion therapy. Annu Rev Med 1980, 31:509-540.
10. Platelet transfusion therapy. JAMA 1987, 257:1777-1780. Members of the Consensus Development Panel.
11. Slichter S., Harker L.A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978, 7:523-529.
12. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997, 337:1870-1875.
13. Gil-Fernandez J.J., Alegre A., Fernandez-Villalta M.J., et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996, 18:931-935.
14. Heckman K.D., Weiner G.J., Davis C.S., et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol 1997, 15:1143-1149.
15. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998, 91:3601-3606.
16. Aderka D., Praff G., Santo M. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic platelet transfusion policy. Am J Med Sci 1986, 291:147-151.
17. Zumberg M.S., del Rosario M.L.U., Nejame C.F., et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/μL versus 20,000/μL trigger. Biol Blood Marrow Transplant 2002, 8:569-576.
18. Beutler E. Platelet transfusions: the 20,000/mL trigger. Blood 1993, 81:1411-1413.
19. Greeno E., McCullough J., Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion 2007, 47:201-205.
20. Harker L.A., Slichter S.J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972, 287:155-159.
21. Bishop J.F., Schiffer C.A., Aisner J., Matthews J.P., Wiernik P.H. Surgery in acute leukemia: a review of 167 operations in thrombocytopenic patients. Am J Hematol 1987, 26:147-155.
22. Platelet transfusion therapy. National Institutes of Health Consensus Conference. Transf Med Rev 1987, 195-200.
23. Norfolk D.R., Ancliffe P.J., Contreras M., et al. Consensus conference on platelet transfusion. Royal College of Physicians of Edinburgh, November 27-28, 1997. Br J Haematol 1998, 101:609-617.
24. Edelson R.N., Chernik N.L., Posner J.B. Spinal subdural hematomas complicating lumbar puncture. Arch Neurol 1974, 31:134-137.
25. Breuer A.C., Tyler R., Marzewski D.J., et al. Radicular vessels are the most probable source of needle induced blood in lumbar puncture. Cancer 1982, 49:2168-2172.
26. Howard S.C., Gajjar A., Ribeiro R.C., et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA 2000, 284:2222-2224.
27. McVay P.A., Toy P.T. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990, 94:747-753.
28. Chu D.Z.J., Shivshanker K., Stroehlein J.R., et al. Thrombocytopenia and gastrointestinal hemorrhage in the cancer patient: prevalence of unmasked lesions. Gastrointest Endosc 1983, 29:269-272.
29. Weiss S.M., Hert R.C., Gianola F.J., et al. Complications of fiberoptic bronchoscopy in thrombocytopenic patients. Chest 1993, 104:1025-1028.
30. Papin T.A., Lynch J.P., Weg J.G. Transbronchial biopsy in the thrombocytopenic patient. Chest 1985, 88:549-552.
31. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002, 346:995-1008.
32. Aster R.H., Jandl J.H. Platelet sequestration in man. II. Immunological and clinical studies. J Clin Invest 1964, 43:856.
33. Baumann M.A., Menitove J.E., Aster R.H., Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 1986, 104:808-809.
34. Murray D.J., Pennell B.J., Weinstein S.L., Olson J.D. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 1995, 80:336-342.
35. Murray D.J., Olson J., Strauss R., Tinker J.H. Coagulation changes during packed red bell replacement of major blood loss. Anesthesiology 1988, 69:839-845.
36. Mannucci P.M., Federici A.B., Sirchia G. Hemostasis testing during massive blood replacement: a study of 172 cases. Vox Sang 1982, 42:113.
37. Counts R.B., Haisch C., Simon T.L., Maxwell N.G., Heimbach D.M., Carrico C.J. Hemostasis in massively transfused trauma patients. Ann Surg 1979, 190-191.
38. Holcomb J.B., Hess J.R. Early massive trauma transfusion: state of the art. J Trauma 2006, 60:S1-S2.
39. Simon T.L., Akl B.F., Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984, 37:359-364.
40. Goodnough L.T., Johnston M.F., Ramsey G., et al. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks. Ann Thorac Surg 1990, 50:675-683.
41. Hersh J.K., Hom E.G., Brecher M.E. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient. Transfusion 1998, 38:637-644.
42. Goodnough L.T., Kuter D.J., McCullough J., et al. Prophylactic platelet transfusions from healthy normal apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001, 98:1346-1351.
43. Klumpp T.R., Herman J.H., Gaughan J.P., et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion 1999, 39:674-681.
44. Cid J., Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion 2007, 47:464-470.
45. Heddle N.M., Cook R.J., Tinmouth A., et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009, 113:1564-1573.
46. Slichter J., Kaufman R., Assmann S.F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage (the PLADO trial). N Engl J Med 2010, 362:600-613.
47. Aster R.H. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965, 26:732-743.
48. Duquesnoy R.J., Anderson A.J., Tomasulo P.A., Aster R.H. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 1979, 54:595-599.
49. Lee E.J., Schiffer C.A. ABO compatibility can influence the results of platelet transfusion: results of a randomized trial. Transfusion 1989, 29:384-389.
50. Heal J.M., Blumberg N., Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987, 709:23-30.
51. Goldfinger D., McGinnis M.A. Rh incompatible platelet transfusions-risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971, 284:942-944.
52. Cid J., Ortin X., Elies E., et al. Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion 2002, 42:173-176.
53. Slichter S.J., Davis K., Enright H., et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005, 105:4106-4114.
54. Aster R.J., Jandl J.H. Platelet sequestration in man. II. Immunological and clinical studies. J Clin Invest 1964, 43:856-869.
55. Bishop J.F., McGrath K., Wolf M.M., et al. Clincal factors influencing the efficacy of pooled platelet transfusions. Blood 1988, 71:383-387.
56. Doughty H.A., Murphy M.F., Metcalfe P., et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994, 66:200-205.
57. Yankee R.A., Graff K.S., Dowling R., Henderson E.S. Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med 1973, 288:760-764.
58. Duquesnoy R.J., Filip D.J., Rodey G.E., et al. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977, 2:219-223.
59. Lohrman H.P., Bull M.I., Decter J.A., et al. Platelet transfusions from HLA compatible unrelated donors to alloimmunized patients. Ann Intern Med 1974, 80:9-14.
60. Moroff G., Garratty G., Heal J.M., et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992, 32:633-640.
61. Rachel J.M., Sinor L.T., Tawfik O.W., et al. A solid-phase red cell adherence test for platelet cross-matching. Med Lab Sci 1985, 42:194-195.
62. Rachel J.M., Summers T.C., Sinor L.T., Plapp F.V. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988, 90:63-68.
63. O'Connell B.A., Lee E.J., Rothko K., Hussein M.A., Schiffer C.A. Selection of histocompatibility apheresis platelet donors by cross-matching random donor platelet concentrates. Blood 1992, 79:527-531.
64. Friedberg R.C., Donnelly S.F., Boyd J.C., Gray L.S., Mintz P.D. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993, 81:3428-3434.
65. Class F.H.J., Smeenk R.J.T., Schmidt R., et al. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981, 9:84-89.
66. Seftel M.D., Growe G.H., Petraszko T. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004, 103:333-339.
67. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997, 337:1861-1869. The Trial to Reduce Alloimmunization to Platelets Study Group.
68. Semple J.W., Freedman J. Recipient antigen-processing pathways of allogeneic platelet antigens: essential mediators of immunity. Transfusion 2002, 42:958-961.
69. Sniecinski I., O'Donnell M.R., Nowicki B., Hill L.R. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988, 71:1402-1407.
70. Saarinen U.M., Kekomaki R., Siimes M.A., Myllylai G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990, 75:512-517.
71. van Marwijk Kooy M., van Prooijen H.C., Moes M., et al. Use of leukocyte depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991, 77:201-205.
72. Heddle N.M., Blajchman M.A. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995, 85:603-606.